Modulated Radiotherapy with Concurrent and Adjuvant Temozolomide for Anaplastic Gliomas: Indian Single-center Data

Overview

Journal Indian J Med Paediatr Oncol

Publisher Thieme

Specialty Oncology

Date 2018 Jan 16

PMID 29333019

Authors

Tejinder Kataria

Trinanjan Basu

Deepak Gupta

Shikha Goyal

Shahida Nasreen

Shyam S Bisht

Ashu Abhishek

Susovan Banerjee

Kushal Narang

Ajaya N Jha

Ishani Mohapatra

Jayesh A Modi

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate early clinical outcome for anaplastic gliomas (AG) treated in the era of modulated radiotherapy (RT) and concurrent plus adjuvant temozolomide (TMZ) in an Indian setting.

Materials And Methods: Fifty-three patients with AGs treated with modulated RT and concurrent (95%) and adjuvant TMZ (90%) were analyzed. About 80% of patients had Karnofsky performance status (KPS) at least 90 with 30% seizure at presentation. Postoperative magnetic resonance imaging was available in 65% cases and RT dose was 60 Gy in 30 fractions. First posttreatment imaging was performed at 1 month and then at 3 and 6 months post-RT and then every 3 months. Kaplan-Meier analysis was used to estimate disease-free survival (DFS) and overall survival (OS), and analysis was done using SPSS version 18.0.

Results: With median follow-up of 25 months, 2-year DFS and OS were 75% and 88%. There were only 5% symptomatic central nerves system and 8% symptomatic hematological toxicities. At the 1 evaluation, 30.4% had complete response (CR), at 3 months 40%, and at 6 months 43%. At 6 months, only 4% had progressive disease. Forty-six patients were evaluable till the last follow-up with and 55% had stable to CR. On univariate analysis for DFS, KPS at presentation >90 ( = 0.001) and response at 6 months ( = 0.02) were significant and for OS KPS at presentation ( = 0.004) alone.

Conclusion: Modulated RT with TMZ among Grade III glioma patients resulted in minimum treatment-related toxicities and encouraging survival. Molecular prognostic markers will determine most favorable groups in future.

References

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

Stenning S, Freedman L, Bleehen N . An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br J Cancer. 1987; 56(1):89-90. PMC: 2001669. DOI: 10.1038/bjc.1987.161. View

Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J . Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2012; 31(3):337-43. PMC: 3732012. DOI: 10.1200/JCO.2012.43.2674. View

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

Shonka N, Theeler B, Cahill D, Yung A, Smith L, Lei X . Outcomes for patients with anaplastic astrocytoma treated with chemoradiation, radiation therapy alone or radiation therapy followed by chemotherapy: a retrospective review within the era of temozolomide. J Neurooncol. 2013; 113(2):305-11. DOI: 10.1007/s11060-013-1116-4. View

Lassman A, Iwamoto F, Cloughesy T, Aldape K, Rivera A, Eichler A . International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011; 13(6):649-59. PMC: 3107101. DOI: 10.1093/neuonc/nor040. View

Lassman A . Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?. CNS Oncol. 2015; 4(5):341-6. PMC: 6082332. DOI: 10.2217/cns.15.36. View

Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F . Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol. 2016; 18(11):1529-1537. PMC: 5063521. DOI: 10.1093/neuonc/now133. View

Lecavalier-Barsoum M, Quon H, Abdulkarim B . Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev. 2014; (5):CD007104. PMC: 7388823. DOI: 10.1002/14651858.CD007104.pub2. View

10.

Speirs C, Simpson J, Robinson C, DeWees T, Tran D, Linette G . Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide. Int J Radiat Oncol Biol Phys. 2015; 91(2):268-76. DOI: 10.1016/j.ijrobp.2014.10.027. View

11.

Paulsson A, McMullen K, Peiffer A, Hinson W, Kearns W, Johnson A . Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Am J Clin Oncol. 2012; 37(2):177-81. PMC: 4485493. DOI: 10.1097/COC.0b013e318271ae03. View

12.

Walker M, ALEXANDER Jr E, HUNT W, MacCARTY C, MAHALEY Jr M, Mealey Jr J . Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978; 49(3):333-43. DOI: 10.3171/jns.1978.49.3.0333. View

13.

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

14.

Salazar O, Rubin P, Feldstein M, Pizzutiello R . High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys. 1979; 5(10):1733-40. DOI: 10.1016/0360-3016(79)90554-6. View

15.

Rajmohan K, Sugur H, Shwetha S, Ramesh A, Thennarasu K, Pandey P . Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach. J Clin Pathol. 2016; 69(8):686-94. DOI: 10.1136/jclinpath-2015-203456. View

16.

Rogne S, Konglund A, Scheie D, Helseth E, Meling T . Anaplastic astrocytomas: survival and prognostic factors in a surgical series. Acta Neurochir (Wien). 2014; 156(6):1053-61. DOI: 10.1007/s00701-014-2053-5. View

17.

Kizilbash S, Giannini C, Voss J, Decker P, Jenkins R, Hardie J . The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. J Neurooncol. 2014; 120(1):85-93. PMC: 4229369. DOI: 10.1007/s11060-014-1520-4. View

18.

Lonardi S, Tosoni A, Brandes A . Adjuvant chemotherapy in the treatment of high grade gliomas. Cancer Treat Rev. 2005; 31(2):79-89. DOI: 10.1016/j.ctrv.2004.12.005. View

19.

Eckel-Passow J, Lachance D, Molinaro A, Walsh K, Decker P, Sicotte H . Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med. 2015; 372(26):2499-508. PMC: 4489704. DOI: 10.1056/NEJMoa1407279. View

20.

Strowd R, Abuali I, Ye X, Lu Y, Grossman S . The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. J Neurooncol. 2016; 127(1):165-71. PMC: 4787612. DOI: 10.1007/s11060-015-2028-2. View